Absence of Both Cytochrome <i>P</i> 450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity
Robert A.B. van Waterschoot(The Netherlands Cancer Institute), Alfred H. Schinkel(Oncode Institute), Rogier W. Rooswinkel(Slotervaartziekenhuis), Hilde Rosing(The Netherlands Cancer Institute), Els Wagenaar(The Netherlands Cancer Institute), Ji‐Ying Song(Oncode Institute), Cornelia M.M. van der Kruijssen(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), Antonius E. van Herwaarden(Radboud University Nijmegen), Jurjen S. Lagas, Olaf van Tellingen(Dutch Cancer Society)
Cited by 97
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884